The sequential administration of growth hormone-releasing hormone followed 120 minutes later by hexarelin, as an effective test to assess the pituitary GH reserve in man.

Micic D, Popovic V, Kendereski A, Peino R, Dieguez C, Casanueva FF

Clinical endocrinology1 Nov 1996Cited by 5 (Europe PMC)

PMID8977750DOI10.1046/j.1365-2265.1996.00841.xPepBankPUB-08977750

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialActivity measurement
In healthy volunteers, only one of 12 subjects tested first with hexarelin had a blunted GH response (< 13 mU/l), against 4 of 12 tested first with GHRH.
In plain wordsIn healthy volunteers, one of 12 people had a weak growth hormone response to hexarelin, compared with 4 of 12 for GHRH.
Peptide
Hexarelin
Outcome
Not applicableIndividual blunted GH responses (<13 mU/l) with hexarelin as first stimulus
Study
n = 12
Comparator
GHRH as first stimulus
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microgram/kg · intravenous · single doseAs given in this study (human).
Source sentences
Summary
Furthermore, individually analysed, only one of the 12 subjects tested first with hexarelin, compared to 4 out of 12 tested with GHRH as first stimulus, presented a blunted response (< 13 mU/l).
2 context sentences(design, population, supporting numbers)
Summary · context
The GH stimuli used were GHRH (1 microgram/kg i.v.) as a pituitary stimulus, and hexarelin (1 microgram/kg i.v.) as a GH stimulus whose main action is hypothalamic.
Summary · context
Eighteen normal volunteers (12 women, 6 men) after giving informed consent.
Report a problemFND-0897775003
02HumanNon-randomized trialActivity measurement
In healthy volunteers, hexarelin given first produced a mean GH peak of 54.7 mU/l.
In plain wordsIn healthy volunteers, a first dose of hexarelin released growth hormone.
Peptide
Hexarelin
Outcome
IncreaseGH peak when hexarelin was the first stimulus
Study
n = 6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microgram/kg · intravenous · single doseAs given in this study (human).
Measurements
GH mean peak
54.7 mU/l
hexarelin as first stimulus
Source sentences
Summary
the hexarelin-stimulated GH mean peak was 54.7 +/- 18.4, and the GH release 120 minutes later after GHRH was 4.8 +/- 1.9 (P < 0.05 vs GHRH used as first stimulus).
2 context sentences(design, population, supporting numbers)
Summary · context
The GH stimuli used were GHRH (1 microgram/kg i.v.) as a pituitary stimulus, and hexarelin (1 microgram/kg i.v.) as a GH stimulus whose main action is hypothalamic.
Summary · context
Eighteen normal volunteers (12 women, 6 men) after giving informed consent.
Report a problemFND-0897775001
03HumanNon-randomized trialActivity measurement
In healthy volunteers, a second hexarelin dose 120 minutes after the first produced a lower GH mean peak than the first dose (P < 0.05).
In plain wordsIn healthy volunteers, a second dose of hexarelin two hours after the first released less growth hormone than the first.
Peptide
Hexarelin
Outcome
DecreaseGH peak after hexarelin 120 minutes after the first hexarelin dose
Study
n = 6
Comparator
First hexarelin dose
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microgram/kg · intravenous · two doses 120 minutes apartAs given in this study (human).
Measurements
GH mean peak
70.6 mU/l
first hexarelin dose
GH mean peak
13.4 mU/l
second hexarelin dose
Source sentences
Summary
Similar results were obtained with hexarelin, with a first mean peak of 70.6 +/- 10.3 mU/l, and a second one 120 minutes later of 13.4 +/- 4.6 mU/l (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The GH stimuli used were GHRH (1 microgram/kg i.v.) as a pituitary stimulus, and hexarelin (1 microgram/kg i.v.) as a GH stimulus whose main action is hypothalamic.
Summary · context
Eighteen normal volunteers (12 women, 6 men) after giving informed consent.
Report a problemFND-0897775002

Studies that did not test the peptide alone4

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

04HumanNot a test of Hexarelin aloneNon-randomized trialActivity measurement
In healthy volunteers, GHRH followed 120 minutes later by hexarelin induced two episodes of GH secretion.
In plain wordsIn healthy volunteers, GHRH followed two hours later by hexarelin released growth hormone twice.
Peptide
Hexarelin
Outcome
IncreaseGH peak after hexarelin 120 minutes after GHRH
Study
n = 6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH mean peak
38.2 mU/l
after GHRH
GH mean peak
56.7 mU/l
after hexarelin 120 minutes later
Source sentences
Summary
GHRH followed 120 minutes later by hexarelin induced two episodes of GH secretion (expressed as mean GH peak, mU/l). The GHRH-mediated GH release showed a mean GH peak of 38.2 +/- 13.6 mU/l and after hexarelin 120 minutes later of 56.7 +/- 18.0 mU/l.
2 context sentences(design, population, supporting numbers)
Summary · context
The GH stimuli used were GHRH (1 microgram/kg i.v.) as a pituitary stimulus, and hexarelin (1 microgram/kg i.v.) as a GH stimulus whose main action is hypothalamic.
Summary · context
Eighteen normal volunteers (12 women, 6 men) after giving informed consent.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0897775004
05HumanNot a test of Hexarelin aloneNon-randomized trialActivity measurement
In healthy volunteers, GHRH given 120 minutes after hexarelin produced a lower GH release than GHRH given first (P < 0.05).
In plain wordsIn healthy volunteers, GHRH given two hours after hexarelin released less growth hormone than GHRH given first.
Peptide
Hexarelin
Outcome
DecreaseGH peak after GHRH given 120 minutes after hexarelin
Study
n = 6
Comparator
GHRH as first stimulus
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH mean peak
4.8 mU/l
GHRH 120 minutes after hexarelin
Source sentences
Summary
The contrary sequence blocked the second stimulus, i.e. the hexarelin-stimulated GH mean peak was 54.7 +/- 18.4, and the GH release 120 minutes later after GHRH was 4.8 +/- 1.9 (P < 0.05 vs GHRH used as first stimulus).
2 context sentences(design, population, supporting numbers)
Summary · context
The GH stimuli used were GHRH (1 microgram/kg i.v.) as a pituitary stimulus, and hexarelin (1 microgram/kg i.v.) as a GH stimulus whose main action is hypothalamic.
Summary · context
Eighteen normal volunteers (12 women, 6 men) after giving informed consent.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0897775005
06HumanNot a test of Hexarelin aloneNon-randomized trialActivity measurement
In healthy volunteers, a prior intravenous dose of GH did not alter the action of hexarelin injected 120 minutes later.
In plain wordsIn healthy volunteers, a dose of growth hormone did not change the response to hexarelin given two hours later.
Peptide
Hexarelin
Outcome
No significant changeHexarelin action after a prior dose of GH
Study
n = 6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
The previous administration of GH (mean peak 115.5 +/- 42.0) did not alter the action of hexarelin injected 120 minutes later, showing a mean peak of 71.9 +/- 11.2.
2 context sentences(design, population, supporting numbers)
Summary · context
The GH stimuli used were GHRH (1 microgram/kg i.v.) as a pituitary stimulus, and hexarelin (1 microgram/kg i.v.) as a GH stimulus whose main action is hypothalamic.
Summary · context
Eighteen normal volunteers (12 women, 6 men) after giving informed consent.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0897775006
07HumanNot a test of Hexarelin aloneNon-randomized trialEfficacy outcome
In healthy volunteers, there were no false negatives after the sequential stimulus of GHRH and hexarelin.
In plain wordsIn healthy volunteers, the test of GHRH followed by hexarelin gave no false negative results.
Peptide
Hexarelin
Outcome
No significant changeFalse negative results with the sequential GHRH then hexarelin test
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
After the sequential stimulus there were no false negatives.
2 context sentences(design, population, supporting numbers)
Summary · context
The GH stimuli used were GHRH (1 microgram/kg i.v.) as a pituitary stimulus, and hexarelin (1 microgram/kg i.v.) as a GH stimulus whose main action is hypothalamic.
Summary · context
Eighteen normal volunteers (12 women, 6 men) after giving informed consent.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0897775007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.